Skip to main content
. 2022 May 20;27:41. doi: 10.1186/s11658-022-00342-8

Fig. 8.

Fig. 8

RAB11B-AS1 reverses the oncogenic roles of METTL16 in HCC. A Migration ability of SNU-398 cells with METTL16 and RAB11B-AS1 concurrent overexpression or control was detected by transwell migration assay. Scale bars, 100 µm. B Invasion ability of SNU-398 cells with METTL16 and RAB11B-AS1 concurrent overexpression or control was detected by transwell invasion assay. Scale bars, 100 µm. C Cellular proliferation of SNU-398 cells with METTL16 and RAB11B-AS1 concurrent overexpression or control was detected by EdU assay. Scale bars, 100 µm. D Cellular proliferation of SNU-398 cells with METTL16 and RAB11B-AS1 concurrent overexpression or control was detected by CCK-8 assay. E Cellular apoptosis of SNU-398 cells with METTL16 and RAB11B-AS1 concurrent overexpression or control was detected by TUNEL assay. Scale bars, 100 µm. F Cellular apoptosis of SNU-398 cells with METTL16 and RAB11B-AS1 concurrent overexpression or control was detected by caspase-3 activity assay. Results are shown as mean ± SD of n = 3 independent experiments. **P < 0.01, ***P < 0.001; ns, not significant, by one-way ANOVA followed by Dunnett’s multiple comparisons test